{"filings":[{"id":1315677,"accession_number":"0001104659-26-078511","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2026-06-29T12:11:25+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune reports Q4 loss of $73.7M; FDA accepts RP1 BLA resubmission for advanced melanoma","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $73.7M in Q4 FY2026; full-year net loss $313.9M.","FDA accepted RP1 BLA resubmission for advanced melanoma; PDUFA Aug 2, 2026, advisory cttee in late July.","Cash $268.9M at March 31, 2026; expected runway into Q1 calendar 2027.","IGNYTE-3 (Phase 3) and REVEAL (Phase 2/3) trials enrolling; REVEAL Phase 2/3 transition expected Q1 2027.","ASCO 2026: RP1+nivo 3-yr OS 47.8%, median OS 32.9 mos; RP2 19% ORR in solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1286476,"accession_number":"0001104659-26-078009","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2026-06-26T12:14:23+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA accepts Replimune's BLA resubmission for RP1 in advanced melanoma; decision by Aug 2","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted as complete, class 1 response; PDUFA goal date August 2, 2026.","Advisory committee meeting expected in late July 2026.","Resubmission based on Phase 2 IGNYTE trial data for RP1 + nivolumab in anti-PD-1 progressed patients.","RP1 (vusolimogene oderparepvec) seeks accelerated approval for advanced melanoma.","CEO notes FDA urgency reflecting significant unmet need and community support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":734476,"accession_number":"0001104659-26-068002","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2026-05-29T13:56:10+00:00","items":["7.01","9.01"],"status":"ready","headline":"Replimune to resubmit RP1 BLA for advanced melanoma; FDA agrees to prioritize review","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company will resubmit BLA in coming days after collaborative FDA dialogue aligns on path forward.","FDA will treat resubmission as urgent matter and prioritize review due to high unmet need.","Approximately 8,500 Americans with advanced melanoma die each year; half fail checkpoint inhibitor therapy.","BLA supported by IGNYTE trial data in patients who progressed on anti-PD-1 therapy.","CEO Sushil Patel expressed gratitude to FDA for commitment to supporting patients and innovation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95092,"accession_number":"0001104659-26-042141","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA issues second CRL for Replimune's RP1 BLA; company plans layoffs and manufacturing scale-back","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA second Complete Response Letter for BLA of RP1 plus nivolumab for advanced melanoma; Replimune disagrees with decision.","Without timely accelerated approval, further development of RP1 not viable; company eliminating jobs and scaling back U.S. manufacturing.","IGNYTE trial: 34% response rate, median duration 24.8 months for RP1 plus nivolumab in patients progressing on anti-PD-1.","Company cites inconsistent FDA process: new review team, contradictions from September 2025 Type A meeting, and lack of communication.","Approximately 8,500 advanced melanoma deaths annually in U.S.; CEO says regulatory failure denies patients needed treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107916,"accession_number":"0001104659-26-009510","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Replimune Q3 net loss $70.9M; cash $269.1M; RP1 BLA PDUFA date April 10, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and short-term investments $269.1M as of Dec 31, 2025; cash runway extended late into Q1 2027.","Net loss for Q3 FY2026 was $70.9M vs $66.3M in prior year quarter; R&D expenses $53.1M.","BLA resubmission for RP1 in anti-PD-1 failed melanoma accepted; FDA PDUFA target action date April 10, 2026.","Amended loan with Hercules: drew $35M, potential additional $120M post-approval; debt repayment delayed to 2027.","Phase 3 IGNYTE-3 confirmatory study for RP1 enrolling ~400 patients; REVEAL Phase 2/3 for RP2 in uveal melanoma actively enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107915,"accession_number":"0001104659-26-002721","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Replimune files updated corporate presentation for J.P. Morgan; exhibit content not available","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company released updated corporate presentation on January 12, 2026.","Presentation to be presented at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.","Presentation covers recent business developments and clinical data for RP1 and RP2 programs.","Exhibit 99.1 text was not provided, preventing detailed analysis of clinical or strategic updates.","No specific financial or clinical figures were disclosed in the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124329,"accession_number":"0001104659-25-107438","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune reports Q2 net loss $83.1M; FDA accepts RP1 BLA resubmission with PDUFA April 10, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $323.6M at Sep 30, 2025, down from $483.8M at Mar 31, 2025.","R&D expenses $57.9M vs $43.4M YoY; S,G&A $26.4M vs $15.5M YoY.","Net loss $83.1M vs $53.1M in prior year quarter.","FDA accepted BLA resubmission for RP1 in advanced melanoma; PDUFA target action date April 10, 2026.","Phase 3 IGNYTE-3 trial enrolling ~400 patients; REVEAL Phase 2/3 for RP2 in uveal melanoma enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124328,"accession_number":"0001104659-25-100605","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts Replimune's BLA resubmission for RP1 in advanced melanoma; PDUFA April 10, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted resubmission of BLA for RP1 plus nivolumab in advanced melanoma patients who progressed on anti-PD-1 therapy.","PDUFA target action date set for April 10, 2026 under Class II resubmission timeline.","Resubmission addresses the complete response letter received in July 2025; includes additional data and analyses.","Replimune CEO expressed commitment to working closely with FDA to expedite review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141005,"accession_number":"0001104659-25-091066","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Replimune completes Type A FDA meeting for RP1 BLA in melanoma; path forward uncertain","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["Completed Type A FDA meeting on Sept 16, 2025 regarding CRL for RP1+nivolumab BLA in advanced melanoma.","Evaluating FDA feedback; accelerated approval path not yet determined.","CEO cites unmet need and compelling IGNYTE trial risk-benefit; committed to working with FDA.","No timeline or resolution provided; stock may remain volatile pending updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141004,"accession_number":"0001104659-25-087464","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Replimune schedules Type A meeting with FDA to discuss RP1 CRL; program viability at risk","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Type A meeting scheduled to discuss CRL for RP1 BLA in advanced melanoma; briefing submitted with additional analysis.","CEO states without accelerated approval, RP1 program in advanced melanoma, including phase 3 confirmatory trial, will not be viable.","Stockholders voted against amending 2018 Omnibus Incentive Compensation Plan (26.97M for, 35.49M against).","All director nominees elected; PwC ratification and say-on-pay proposals approved by stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141003,"accession_number":"0001104659-25-074989","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune reports Q1 FY2026 net loss $86.7M; FDA issues CRL for RP1 BLA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $86.7M for quarter ended June 30, 2025, vs $53.8M a year ago.","Cash, cash equivalents and short-term investments $403.3M; funding expected into Q4 2026.","FDA issued Complete Response Letter for RP1 BLA in advanced melanoma on July 22, 2025.","R&D expenses $57.8M (up from $43.0M); SG&A $32.6M (up from $14.4M), driven by commercial prep.","Ongoing Phase 3 IGNYTE-3 trial for RP1+nivolumab; Phase 2/3 REVEAL trial for RP2 in uveal melanoma."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141002,"accession_number":"0001104659-25-069489","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Replimune receives FDA Complete Response Letter for RP1 BLA in advanced melanoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issues CRL for RP1 + nivolumab; IGNYTE trial deemed not adequate/well-controlled.","CRL cites heterogeneous patient population and need to address confirmatory trial design.","No safety issues raised; Company requests Type A meeting within 30 days.","CEO surprised as issues not raised during mid- or late-cycle reviews.","Without accelerated approval, RP1 development for advanced melanoma patients not viable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158772,"accession_number":"0001104659-25-062122","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Replimune hosts Investor Day on June 24, 2025; updated presentation posted online","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor Day webcast and updated presentation deck available under Events and Presentations on company website.","No financial results, pipeline updates, or guidance changes were disclosed in the 8-K filing.","Company directs investors to monitor its website for material non-public information per Regulation FD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158771,"accession_number":"0001104659-25-051847","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune Q4 net loss $74.1M; RP1 BLA on track for July 22 PDUFA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 $74.1M, FY $247.3M; cash $483.8M, runway into Q4 2026 excluding revenue.","BLA for RP1+nivolumab in advanced melanoma on schedule; PDUFA July 22, 2025; no advisory committee.","Commercial infrastructure fully built and ready for launch; distribution channels established.","R&D Q4 $54.0M (+27% YoY); SG&A Q4 $25.4M (+57% YoY) driven by pre-launch scaling.","Investor day June 24; confirmatory Phase 3 IGNYTE-3 enrolling 400 patients globally."],"consensus_eps_estimate":-0.9078,"consensus_eps_actual":-3.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177183,"accession_number":"0001104659-25-021756","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Replimune appoints Michael Goller to board; enters registration rights with BBA Funds","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Goller appointed to Board on March 5, 2025; board expanded to 10 members.","Goller is an employee of Baker Bros. Advisors LP; received option for 64,000 shares at $12.29.","Company entered Affiliate Registration Rights Agreement with BBA Funds for resale registration of their shares.","BBA Funds participated in June 2024 private placement ($96.7M net) and Nov 2024 public offering ($156M net).","Agreement allows up to one underwritten offering per year, max three total, and up to two offerings/trades per year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177182,"accession_number":"0001104659-25-011851","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune Q3 net loss $66.3M; FDA accepts RP1 BLA with priority review, PDUFA July 22","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted BLA for RP1+nivolumab in advanced melanoma with Priority Review; PDUFA date July 22, 2025.","Net loss $66.3M for fiscal Q3 2025, up from $51.1M in Q3 2024; R&D expense $48.0M.","Cash & investments $536.5M as of Dec 31, 2024, expected to fund operations into Q4 2026.","Public offering raised ~$156M net to support RPx development and potential commercial launch.","First patients enrolled in RP2 registration-directed trial for uveal melanoma and Phase 2 HCC trial."],"consensus_eps_estimate":-0.8013,"consensus_eps_actual":-2.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177181,"accession_number":"0001104659-25-005291","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Replimune BLA for RP1+nivolumab in advanced melanoma accepted with Priority Review; PDUFA July 22, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted BLA for RP1 (vusolimogene oderparepvec) plus nivolumab for advanced melanoma; granted Priority Review.","PDUFA action date set for July 22, 2025; no advisory committee meeting currently planned.","BLA supported by primary analysis from IGNYTE trial in anti-PD-1 failed melanoma patients.","Confirmatory Phase 3 IGNYTE-3 trial ongoing with over 100 planned sites globally.","Replimune previously received Breakthrough Therapy designation for this combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193954,"accession_number":"0001104659-24-125370","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K/A","filed_at":"2024-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Replimune closes $155.8M public offering of stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 6,923,000 common shares at $13.00 and 3,846,184 pre-funded warrants at $12.9999 each, raising ~$155.8M net.","Underwriter's over-allotment option for 1,615,377 additional shares exercised in full.","Pre-funded warrants have $0.0001 exercise price; beneficial ownership cap corrected to 19.99% in this amendment.","Shares and warrants sold pursuant to effective shelf registration; expected closing Nov 27 and Dec 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193958,"accession_number":"0001104659-24-123451","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Replimune prices upsized public offering of ~$140M; 6.9M shares + pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 6,923,000 common shares at $13.00/share and pre-funded warrants for 3,846,184 shares at $12.9999 each.","Gross proceeds ~$140M; net proceeds estimated at ~$155.8M after full exercise of underwriter option.","Leerink Partners sole bookrunner; closing expected Nov 27, 2024.","Underwriter's 30-day option for 1,615,377 additional shares exercised in full."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193957,"accession_number":"0001104659-24-122860","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Replimune reduces ATM offering capacity from $100M to $89M, suspends sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate offering amount cut from $100M to $89M via Amendment No. 2 dated Nov 25, 2024.","Company suspending ATM prospectus; no sales until new prospectus or registration statement filed.","Amendment entered with Leerink Partners LLC; Sales Agreement otherwise remains in effect.","Reduction and suspension are precautionary; no current sales are being made under ATM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193956,"accession_number":"0001104659-24-121616","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Replimune submits BLA for RP1+nivolumab in advanced melanoma under Accelerated Approval; FDA grants Breakthrough Therapy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BLA submitted to FDA for RP1 (vusolimogene oderparepvec) + nivolumab in advanced melanoma patients previously treated with anti-PD1.","Submission under Accelerated Approval pathway; based on safety and activity in IGNYTE trial.","FDA granted Breakthrough Therapy designation for RP1 + nivolumab in same setting.","Confirmatory Phase 3 IGNYTE-3 trial enrolling patients with prior anti-PD1 and anti-CTLA-4 therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193955,"accession_number":"0001104659-24-116413","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune reports Q2 FY2025 net loss $53.1M; BLA for RP1 in melanoma on track before year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed pre-BLA meeting with FDA; BLA submission for RP1+nivolumab in anti-PD1 failed melanoma via accelerated approval path on track by end of 2024.","IGNYTE primary analysis: 33.6% ORR at 12 months by modified RECIST 1.1; median DOR from response initiation 21.6 months.","Cash, cash equivalents and short-term investments $432.1M as of Sep 30, 2024; funding operations into H2 2026.","R&D expenses $43.4M, down from $49.1M; net loss $53.1M, improved from $60.0M YoY.","RP2 in uveal melanoma: registration-directed trial with first patient enrollment expected Q1 2025."],"consensus_eps_estimate":-0.8234,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210280,"accession_number":"0001104659-24-097365","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Replimune shareholders elect three Class III directors and ratify auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors elected: Sushil Patel (54.6M for), Dieter Weinand (46.9M for), Madhavan Balachandran (54.6M for).","Ratification of PricewaterhouseCoopers as auditor for FY2025: 62.7M for, 4.4K against.","Say-on-pay advisory approval passed: 53.6M for, 1.0M against.","Frequency of say-on-pay set at every 1 year: 54.2M for 1 year, 421.6K for 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210279,"accession_number":"0001104659-24-087035","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune Q1 FY2025: $53.8M net loss, $469.1M cash; RP1 BLA on track for 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $53.8M for Q1 ended June 30, 2024, up from $49.6M YoY; R&D expenses $43.0M versus $40.4M.","Cash, cash equivalents and short-term investments $469.1M; $96.7M net PIPE financing supports operations into 2H 2026.","Pre-BLA meeting with FDA scheduled for September 2024; RP1 BLA submission planned for 2H 2024.","First patient enrollment in Phase 3 confirmatory IGNYTE-3 trial for RP1 in anti-PD1 failed melanoma expected Q3 2024.","Protocol finalized for registration-directed study of RP2 in uveal melanoma; Phase 2 HCC trial first patient expected 2H 2024."],"consensus_eps_estimate":-0.7677,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228586,"accession_number":"0001104659-24-071078","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Replimune raises $100M in PIPE to fund RP1 commercialization; BLA filing on track for 2H 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 5.67M shares at $8.82/share and 5.67M pre-funded warrants at $8.819/warrant.","Gross proceeds ~$100M; expected closing June 14, 2024.","Proceeds to fully scale up for RP1 commercial launch in skin cancers, potential path to profitability.","Led by life-sciences institutional investor; Redmile, RTW, Boxer Capital participated.","RP1 IGNYTE trial in anti-PD1 failed melanoma showed strong data; BLA submission expected 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228585,"accession_number":"0001104659-24-068948","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Replimune reports positive IGNYTE primary analysis: ORR 33.6% in anti-PD1 failed melanoma; BLA submission planned 2H2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary analysis shows ORR 33.6% (modified RECIST 1.1) and 32.9% (RECIST 1.1) by independent central review; all responses >6 months, median DOR >35 months.","BLA submission intended for 2H2024; confirmatory IGNYTE-3 trial first patient expected Q3 2024.","Safety: predominantly Grade 1-2 constitutional events; no Grade 5 events; low incidence of Grade 3-4 incidents.","Data improves on investigator-assessed results presented at ASCO 2024; FDA-requested RECIST 1.1 analysis included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228584,"accession_number":"0001104659-24-067556","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Replimune presents positive RP1/RP2 data at ASCO: 32.7% ORR in melanoma, BLA on track for 2H 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RP1+nivolumab in anti-PD-1 failed melanoma (n=156) showed 32.7% ORR by investigator; median duration of response >36 months.","In primary resistant patients (n=94) ORR 34%; in anti-PD-1+anti-CTLA-4 progressors (n=66) ORR 27.3%.","RP2 in uveal melanoma (n=17) showed 29.4% ORR and 58.8% DCR as monotherapy or with nivolumab; registration-directed trial planned.","Company expects central review results Q2 2024; BLA submission for RP1 in 2H 2024; Phase 3 IGNYTE-3 to start before BLA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228583,"accession_number":"0001104659-24-062296","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune posts Q4 net loss $55.1M; RP1 melanoma BLA on track for 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $55.1M for Q4 FY2024; full-year net loss $215.8M vs $174.3M prior year.","Cash, equivalents & investments $420.7M; cash runway projected into 2H 2026.","Primary analysis of IGNYTE trial (RP1 + nivolumab) in anti-PD1 failed melanoma expected Q2 2024.","BLA submission for RP1 in anti-PD1 failed melanoma planned for 2H 2024 after positive FDA CMC meeting.","First patient enrollment in Phase 3 IGNYTE-3 confirmatory trial expected 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247240,"accession_number":"0001104659-24-038705","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Replimune names Sushil Patel CEO effective April 1; Astley-Sparke becomes Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sushil Patel appointed CEO effective April 1, 2024; previously Chief Strategy Officer.","Philip Astley-Sparke transitions from CEO to Executive Chairman; Dieter Weinand becomes Lead Independent Director.","Robert Coffin moves to Founder & Chief Scientist advisory role; Paul Bullock promoted to Chief Manufacturing Officer.","Colin Love (COO) retiring May 31; Pamela Esposito and Tanya Lewis leave executive roles but remain advisors.","Company on track to submit RP1 BLA in 2H 2024 for anti-PD1 failed melanoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247239,"accession_number":"0001104659-24-011951","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune reports Q3 FY2024 net loss $51.1M; cash $466.4M; RP1 BLA plan for 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $51.1M for Q3 FY2024, up from $39.7M in prior year; R&D expenses $42.8M vs $30.3M.","Cash, equivalents & short-term investments $466.4M as of Dec 31, 2023; cash runway extended into 2H 2026.","BLA submission for RP1 in anti-PD1 failed melanoma planned for 2H 2024; Phase 3 confirmatory trial to start 2H 2024.","RP2 data in uveal melanoma positive; planning for potential registrational trial in advanced uveal melanoma."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247238,"accession_number":"0001104659-24-002072","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Replimune reports ~$466M cash, runway into 2H 2026; updates RP1/RP2 clinical data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash and equivalents of ~$466M as of Dec 31, 2023; funds operations into second half of 2026.","Updated clinical data for RP1 and RP2 presented at 42nd J.P. Morgan Healthcare Conference.","Cash estimate is unaudited, subject to completion of quarterly closing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264674,"accession_number":"0001104659-23-129266","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2023-12-26T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Replimune amends Hercules loan: extends revenue milestone to 2026, adjusts tranches up to $50M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second tranche cut from $45M to $15M (funded Dec 22, 2023); third tranche raised to $30M, extended to Mar 2025.","Fourth tranche increased from $35M to $50M; fifth tranche increased from $40M to $50M, both extended to Mar 2026 and Sep 2026 respectively.","Revenue milestone date for triggering loan conditions extended from prior date to July 31, 2026.","Amendment with Hercules Capital as agent; terms affect up to $145M in potential future advances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264673,"accession_number":"0001104659-23-123459","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Replimune CERPASS trial misses primary endpoints; BLA for RP1 in melanoma planned 2H 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CERPASS trial of RP1+cemiplimab in CSCC did not meet primary endpoints; CRR 38.1% vs 25% (p=0.040 just below threshold).","In anti-PD1 failed melanoma (IGNYTE, n=156), ORR 31.4% (12% CR); median DOR >24 months; BLA submission planned for 2H 2024.","RP1 monotherapy (ARTACUS) in transplant patients: 34.8% ORR, 5 CRs, no allograft rejection.","Portfolio reprioritization: discontinue RP2/3 in SCCHN/CRC and RP3 development; focus on RP1 melanoma and RP2 uveal melanoma.","Cash $496.8M as of Sept 30, 2023; cash runway extended into early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264672,"accession_number":"0001104659-23-115027","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune Q2 FY2024 net loss $60M; cash $496.8M; RP1 data and new CFO announced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $60.0M for Q2 ended Sep 30, 2023, compared to $43.1M loss a year ago.","Cash, equivalents & short-term investments $496.8M as of Sep 30, 2023; funds operations into H2 2025.","R&D expenses $49.1M (up from $28.8M) driven by clinical and manufacturing costs for lead programs.","Appointed Emily Hill as CFO; she was previously CFO of PTC Therapeutics.","Topline CERPASS trial data and initial IGNYTE melanoma snapshot expected in early December 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281909,"accession_number":"0001104659-23-101773","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2023-09-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Replimune names Emily Hill as CFO; previously CFO of PTC Therapeutics","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Emily Hill as CFO effective Sept 18, 2023; she was previously CFO of PTC Therapeutics.","Base salary $495,000, target bonus 40%, plus 125,000 stock options at $18.00 and 83,330 RSUs, vesting over 4 years.","Termination benefits: 12 months salary plus COBRA; enhanced upon change of control.","Ms. Hill brings 15+ years biotech experience, including roles at PTC, Warner Chilcott, and Genzyme."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281908,"accession_number":"0001104659-23-098814","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Replimune stockholders elect two Class II directors, ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Paolo Pucci elected with 25,146,894 votes for and 21,307,605 withheld; 5,424,721 broker non-votes.","Veleka Peeples-Dyer elected with 43,195,979 votes for and 3,258,520 withheld; broker non-votes same.","Ratification of PricewaterhouseCoopers as auditor passed: 51,869,761 for, 4,084 against, 5,375 abstain.","Annual meeting held September 6, 2023; all proposals approved per proxy statement filed July 26, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281907,"accession_number":"0001104659-23-087083","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Replimune enters $250M at-the-market equity agreement with Leerink, cancels prior $100M ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Sales Agreement with Leerink Partners allows sale of up to $250M of common stock via ATM or negotiated transactions.","Agent commission up to 3% of gross proceeds; Company controls timing and size of sales.","Prior $100M ATM program terminated concurrently with the new agreement.","No shares sold yet; Company may issue none under the new facility.","Registration statement on Form S-3 filed same day for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281906,"accession_number":"0001104659-23-087059","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Replimune Q1 net loss $49.6M; CERPASS data delayed to early Q4; inks Incyte CSCC trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $49.6M in fiscal Q1 vs $42.3M a year ago; cash $539.1M provides runway into H2 2025.","CERPASS topline data (RP1+Libtayo in CSCC) expected early Q4 2023, delayed from Q3 due to slower independent review.","IGNYTE full cohort snapshot (N=141) in anti-PD1 failed melanoma on track for Q4 2023; BLA submission planned Q1/Q2 2024.","Clinical trial collaboration with Incyte to test RP1 + oral PD-L1 INCB99280 in neoadjuvant CSCC; trial to start early 2024, costs shared.","RP2/RP3 Phase 2 programs: third-line CRC trial initiated; HCC trial expected this quarter; Phase 1 completion in Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281905,"accession_number":"0001104659-23-082566","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sander Slootweg to leave Replimune board at 2023 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sander Slootweg, founder/managing partner at Forbion, will not stand for reelection at the upcoming annual meeting.","Departure is not due to any dispute or disagreement with Replimune or its management.","Slootweg served as non-executive director since company's inception; CEO expresses gratitude for his service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300910,"accession_number":"0001104659-23-067856","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Replimune appoints Veleka Peeples-Dyer to Board of Directors, effective June 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Veleka Peeples-Dyer appointed to Board as tenth member, filling vacancy from Board size increase.","She also joins the Audit Committee, replacing Dieter Weinand; receives annual retainers of $45,000 (Board) and $10,000 (Audit).","Granted nonqualified stock option for 50,400 shares at $18.48 strike, vesting 25% after one year then monthly over 24 months.","Ms. Peeples-Dyer brings over 24 years of life sciences legal and compliance experience, including executive roles at biopharma companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300909,"accession_number":"0001104659-23-062103","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Replimune reports Q4 FY2023 net loss $49.2M, CFO Franchi resigns, cash $583.4M into H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $49.2M, FY net loss $174.3M vs $118.0M prior year; R&D spend $126.5M up 59% YoY.","Cash $583.4M as of Mar 31, 2023, providing runway into H2 2025; $311.4M raised in financing during year.","CFO Jean Franchi resigns effective June 2, 2023; consulting through Dec 31, 2023 with $483K severance.","Andrew Schwendenman appointed Chief Accounting Officer; CEO Astley-Sparke serves as interim CFO.","CERPASS topline data expected Q3 2023; BLA submission for RP1 in CSCC planned Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320794,"accession_number":"0001104659-23-025680","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Replimune provides FDA update on CERPASS trial; no changes to protocol or endpoints","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed no changes to CERPASS clinical trial protocol or data analysis plan after meeting.","Minor changes to statistical analysis plan (SAP) unrelated to dual primary endpoints (ORR and CRR).","Company still expects BLA submission for RP1 in early 2024, assuming positive data and overall clinical benefit.","This update follows FDA response to draft SAP submitted in September 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320793,"accession_number":"0001104659-23-014934","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune Q3 net loss $39.7M; cash $616M; RP1 melanoma achieves 36% ORR in IGNYTE cohort","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $39.7M for fiscal Q3 ended Dec 31, 2022 vs $29.7M YoY; R&D expenses rose to $30.3M.","Raised ~$259M gross in upsized public offering; secured $200M non-dilutive debt facility ($30M drawn); cash runway into H2 2025.","Topline data from CERPASS trial (RP1+cemiplimab in CSCC) delayed to Q3 2023 from prior H1 2023.","IGNYTE cohort of RP1+Opdivo in anti-PD1 failed melanoma: 36% ORR, 20% CR in first 75 patients; target enrollment of 125 reached.","Collaboration with Roche for RP2/3 in CRC and HCC; appointed Christopher Sarchi as CCO."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320792,"accession_number":"0001104659-23-000666","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Replimune appoints Chris Sarchi as CCO and Sushil Patel as Chief Strategy Officer, effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Sarchi, former Sanofi U.S. Commercial Oncology Head, named Chief Commercial Officer.","Sushil Patel, previously CCO, transitions to newly created Chief Strategy Officer role.","Appointments aim to ramp up commercial planning ahead of potential 2024 launch of RP1.","Sarchi led Libtayo launch in CSCC; Patel will lead ex-U.S. strategy and platform planning."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338933,"accession_number":"0001104659-22-126323","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Replimune prices $225M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5.37M shares at $23.50/share and pre-funded warrants for 4.20M shares at $23.4999/warrant.","Underwriters' 30-day option for 1.44M additional shares exercised in full.","Net proceeds estimated at $242.6M after underwriting discounts and expenses.","Offering expected to close December 13, 2022, funded from shelf registration.","J.P. Morgan, SVB Securities, Piper Sandler, and BMO Capital Markets are joint book-runners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338932,"accession_number":"0001104659-22-125054","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Replimune reports 36% ORR in anti-PD1 failed melanoma; enters Roche collaboration for RP2/3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration with Roche to develop RP3 with atezolizumab/bevacizumab in 3L CRC and 1L/2L HCC; cost sharing; Phase 2 start H1 2023.","IGNYTE anti-PD1 failed melanoma: 36% ORR, 20% CR rate in first 75 patients; 85% of responses ongoing; systemic activity seen.","RP2/3 update: uveal melanoma 28.6% ORR (4/14 evaluable); soft tissue sarcoma 3/5 responding; responses durable.","Phase 2 plans for RP2/3: SCCHN (130 patients), HCC (60), CRC (60); enrollment in H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338931,"accession_number":"0001104659-22-114224","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune Q2 net loss $43.1M; CERPASS enrollment complete, cash runway extended into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $43.1M for Q2 FY2022 (vs $29.4M in Q2 FY2021); R&D expenses $28.8M.","Completed enrollment in CERPASS trial (n=211) of RP1+Libtayo in CSCC; primary data expected H1 2023.","Six-month data from first 75 patients in IGNYTE (RP1+Opdivo anti-PD1 failed melanoma) expected by year-end.","Closed $200M term loan with Hercules Capital; cash and investments $371.8M as of Sep 30, 2022.","Cash runway extended into 2025, covering commercial infrastructure and confirmatory trial costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338930,"accession_number":"0001104659-22-106936","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2022-10-07T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Replimune secures $200M non-dilutive debt facility from Hercules Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$200M term loan; $30M funded at closing, $30M available by Sep 30, 2023.","Up to $115M available upon clinical/regulatory/commercial milestones; $25M subject to Hercules consent.","Interest: floating cash rate (greater of 7.25% or Prime+1.75% capped at 7.25%) plus 1.50% PIK.","At least 48 months interest-only, extendable to 60 months on milestone achievement; matures Oct 2027.","Proceeds extend cash runway into 2025 ahead of CERPASS/IGNYTE trial catalysts and commercial prep."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356309,"accession_number":"0001104659-22-098536","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2022-09-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Replimune holds annual meeting; elects directors, ratifies PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Philip Astley-Sparke elected with 31,308,902 votes for, 5,731,814 withheld, 7,702,397 broker non-votes.","Kapil Dhingra elected with 20,779,414 votes for, 16,261,302 withheld, 7,702,397 broker non-votes.","Joseph Slattery elected with 30,750,118 votes for, 6,290,598 withheld, 7,702,397 broker non-votes.","Christy Oliger elected with 35,395,002 votes for, 1,645,714 withheld, 7,702,397 broker non-votes.","Ratification of PricewaterhouseCoopers LLP as auditor for FY2023: 44,739,639 for, 2,370 against, 1,104 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356308,"accession_number":"0001104659-22-085894","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune Q1 net loss $42.3M; CERPASS trial hits 180-patient enrollment target","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & short-term investments $395.1M as of June 30, 2022, vs $395.7M at March 31, 2022.","Net loss $42.3M for Q1 ended June 30, 2022, up from $27.3M year-over-year; R&D expenses rose to $29.5M.","CERPASS registration trial for RP1 in CSCC reached target enrollment of 180 patients; primary data expected H1 2023.","First 75 patients enrolled in IGNYTE anti-PD1 failed melanoma cohort; data snapshot with 6-month follow-up expected Q4 2022.","Phase 2 development program for RP2/3 in SCCHN, HCC, and CRC expected to initiate Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-04T23:59:59+00:00|356308"}